enGene Holdings Inc. (NASDAQ:ENGNW) Sees Significant Drop in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 399 shares, a decrease of 90.9% from the April 15th total of 4,399 shares. Based on an average trading volume of 8,555 shares, the short-interest ratio is presently 0.0 days.

enGene Stock Up 26.7%

ENGNW traded up $0.03 on Monday, hitting $0.15. 86,293 shares of the company traded hands, compared to its average volume of 18,109. The company has a 50 day moving average of $2.29 and a 200-day moving average of $2.61. enGene has a 12-month low of $0.11 and a 12-month high of $4.20.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.